[
  {
    "ts": null,
    "headline": "Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today",
    "summary": "Bristol Myers Squibb (BMY) closed the most recent trading day at $56.30, moving -0.95% from the previous trading session.",
    "url": "https://finnhub.io/api/news?id=8e330eb896238614a0037533a4f6a7c6765985d1b87d445d3982bea33e0e20e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734648321,
      "headline": "Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today",
      "id": 132060931,
      "image": "https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb (BMY) closed the most recent trading day at $56.30, moving -0.95% from the previous trading session.",
      "url": "https://finnhub.io/api/news?id=8e330eb896238614a0037533a4f6a7c6765985d1b87d445d3982bea33e0e20e2"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Stock Earns 83 RS Rating",
    "summary": "On Thursday, Bristol Myers Squibb stock got a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83. IBD's proprietary rating tracks price performance with a 1 (worst) to 99 (best) score.",
    "url": "https://finnhub.io/api/news?id=522062198c1b1630c2f1f86e4b367dd1badd36916e04aa7d08a19dbabc982ed6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734636480,
      "headline": "Bristol Myers Squibb Stock Earns 83 RS Rating",
      "id": 132057057,
      "image": "https://media.zenfs.com/en/ibd.com/34cca67fae26bc0f236698386833518e",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "On Thursday, Bristol Myers Squibb stock got a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83. IBD's proprietary rating tracks price performance with a 1 (worst) to 99 (best) score.",
      "url": "https://finnhub.io/api/news?id=522062198c1b1630c2f1f86e4b367dd1badd36916e04aa7d08a19dbabc982ed6"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Bristol-Myers Squibb (BMY): Why Schizophrenia Drug Cobenfy Could Change the Game",
    "summary": "We recently published a list of the Jim Cramer Just Discussed These 13 Stocks. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other stocks that Jim Cramer discussed recently. As the Federal Reserve exits the year by having continued its interest rate cuts, Wall Street […]",
    "url": "https://finnhub.io/api/news?id=8ded74f8f1b486af3f2fe33801fd67bde68ea9283fdf8de867a843ceb699c9db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734630125,
      "headline": "Jim Cramer on Bristol-Myers Squibb (BMY): Why Schizophrenia Drug Cobenfy Could Change the Game",
      "id": 132057058,
      "image": "https://s.yimg.com/ny/api/res/1.2/ZsrqNB_sdV78LPtS9DZ12A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/4da437b7638100421dc4d0ddd5060036",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently published a list of the Jim Cramer Just Discussed These 13 Stocks. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other stocks that Jim Cramer discussed recently. As the Federal Reserve exits the year by having continued its interest rate cuts, Wall Street […]",
      "url": "https://finnhub.io/api/news?id=8ded74f8f1b486af3f2fe33801fd67bde68ea9283fdf8de867a843ceb699c9db"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=b89dbae061233cdaacdc1bff30a68e271eb3a2b0f5a0868b5589e145831f9431",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734626460,
      "headline": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
      "id": 132148494,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=b89dbae061233cdaacdc1bff30a68e271eb3a2b0f5a0868b5589e145831f9431"
    }
  },
  {
    "ts": null,
    "headline": "3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income",
    "summary": "If you're a retiree and want some dependable income, high-yielding dividend stocks can help make the most of your money.  For retirees, three blue chip stocks that can be ideal options for your portfolio include Bristol Myers Squibb (NYSE: BMY), Enbridge (NYSE: ENB), and Coca-Cola (NYSE: KO).  Drugmaker Bristol Myers pays a dividend that yields 4.5% right now.",
    "url": "https://finnhub.io/api/news?id=b90d9ce05d741fa2dfd682a181e8840f8f5393f33a621c769a686143db8dd461",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734620400,
      "headline": "3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income",
      "id": 132052284,
      "image": "https://g.foolcdn.com/editorial/images/801016/a-couple-looking-at-a-statement.jpg",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "If you're a retiree and want some dependable income, high-yielding dividend stocks can help make the most of your money.  For retirees, three blue chip stocks that can be ideal options for your portfolio include Bristol Myers Squibb (NYSE: BMY), Enbridge (NYSE: ENB), and Coca-Cola (NYSE: KO).  Drugmaker Bristol Myers pays a dividend that yields 4.5% right now.",
      "url": "https://finnhub.io/api/news?id=b90d9ce05d741fa2dfd682a181e8840f8f5393f33a621c769a686143db8dd461"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025",
    "summary": "PRINCETON, N.J., December 19, 2024--Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025",
    "url": "https://finnhub.io/api/news?id=f5187f0ae1fb39778470586b42128ac3bfbf71d70803dbb6cb11e90d8ed34484",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734609540,
      "headline": "Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025",
      "id": 132057060,
      "image": "https://s.yimg.com/ny/api/res/1.2/2Gm8YL97RF85Uv8yAuj11A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xNjU-/https://media.zenfs.com/en/business-wire.com/e093c05ee48eb83c212687787716eb4a",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., December 19, 2024--Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025",
      "url": "https://finnhub.io/api/news?id=f5187f0ae1fb39778470586b42128ac3bfbf71d70803dbb6cb11e90d8ed34484"
    }
  },
  {
    "ts": null,
    "headline": "Got $250? 2 Healthcare Stocks to Buy and Hold Forever",
    "summary": "One of the great things about the stock market is that one doesn't have to be a genius or a multimillionaire to take advantage of its wealth-building power.  Let's consider two companies in the healthcare sector that look like excellent long-term bets: Bristol Myers Squibb (NYSE: BMY) and Novo Nordisk (NYSE: NVO).  If you have $250 to spare now, putting that money to work by investing in these healthcare leaders would be a great move.",
    "url": "https://finnhub.io/api/news?id=19f7c5537753d08551d727f5f05fb67d75c6d1407dfdca48bc0ed411f553df59",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734606900,
      "headline": "Got $250? 2 Healthcare Stocks to Buy and Hold Forever",
      "id": 132051886,
      "image": "https://g.foolcdn.com/editorial/images/801148/elderly-person-sitting-on-a-bed.jpg",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "One of the great things about the stock market is that one doesn't have to be a genius or a multimillionaire to take advantage of its wealth-building power.  Let's consider two companies in the healthcare sector that look like excellent long-term bets: Bristol Myers Squibb (NYSE: BMY) and Novo Nordisk (NYSE: NVO).  If you have $250 to spare now, putting that money to work by investing in these healthcare leaders would be a great move.",
      "url": "https://finnhub.io/api/news?id=19f7c5537753d08551d727f5f05fb67d75c6d1407dfdca48bc0ed411f553df59"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?",
    "summary": "It isn't easy to find steady and reliable dividend payers in the pharmaceutical industry.  What's more, since the new payouts will represent the two companies' first dividends of 2025, there's still time for investors to take advantage of them.  You would be hard-pressed to find a pharmaceutical sector dividend that's as reliable as that of Bristol Myers Squibb's. The company has been doling out a shareholder distribution for 93 years.",
    "url": "https://finnhub.io/api/news?id=c1c350b30832646f1320d7bcbcd48748370f7d468a13306ab4e8d2b00fb82995",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734603960,
      "headline": "These 2 Stocks Just Declared Dividend Raises That Kick In Next Year. Should You Buy?",
      "id": 132054704,
      "image": "https://g.foolcdn.com/editorial/images/801021/two-people-in-white-lab-coats-looking-at-a-computer-display.jpg",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "It isn't easy to find steady and reliable dividend payers in the pharmaceutical industry.  What's more, since the new payouts will represent the two companies' first dividends of 2025, there's still time for investors to take advantage of them.  You would be hard-pressed to find a pharmaceutical sector dividend that's as reliable as that of Bristol Myers Squibb's. The company has been doling out a shareholder distribution for 93 years.",
      "url": "https://finnhub.io/api/news?id=c1c350b30832646f1320d7bcbcd48748370f7d468a13306ab4e8d2b00fb82995"
    }
  },
  {
    "ts": null,
    "headline": "Impax Small Cap Fund Q3 2024 Commentary",
    "summary": "The Impax Small Cap Fund outperformed its benchmark in Q3 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=ab72bcbc7d1f69948809802b9801ce65775db233e4bdca3dd409ca6218949ce7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734603300,
      "headline": "Impax Small Cap Fund Q3 2024 Commentary",
      "id": 132052035,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2162096672/image_2162096672.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "The Impax Small Cap Fund outperformed its benchmark in Q3 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=ab72bcbc7d1f69948809802b9801ce65775db233e4bdca3dd409ca6218949ce7"
    }
  }
]